Published in Mol Biochem Parasitol on January 01, 1985
Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci U S A (1990) 3.98
Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (1997) 3.61
Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother (1998) 1.34
In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother (1995) 1.21
Inhibition of Plasmodium falciparum dihydropteroate synthetase and growth in vitro by sulfa drugs. Antimicrob Agents Chemother (1991) 1.17
Targeting purine and pyrimidine metabolism in human apicomplexan parasites. Curr Drug Targets (2007) 1.14
Sulfadoxine-pyrimethamine resistance in the rodent malaria parasite Plasmodium chabaudi. Antimicrob Agents Chemother (2002) 1.01
Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium. Trends Parasitol (2005) 0.94
Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob Agents Chemother (2003) 0.94
A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine. PLoS Clin Trials (2006) 0.91
Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. Int J Parasitol Drugs Drug Resist (2012) 0.83
2,4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials. Antimicrob Agents Chemother (2005) 0.82
The molecular basis of folate salvage in Plasmodium falciparum: characterization of two folate transporters. J Biol Chem (2011) 0.81
Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy. Malar J (2012) 0.79
Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother (1979) 17.49
Averting a malaria disaster. Lancet (1999) 9.40
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis (1997) 4.66
Changing home treatment of childhood fevers by training shop keepers in rural Kenya. Trop Med Int Health (1999) 4.43
Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya. Lancet (1990) 4.17
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol (2001) 3.84
Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. Science (1989) 3.83
Amebiasis: epidemiologic studies in the United States, 1971-1974. Ann Intern Med (1978) 3.58
Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis (2001) 3.43
Current concepts in parasitology. Amebiasis. N Engl J Med (1978) 3.41
Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem (1994) 3.34
Blood-group substances. Science (1966) 3.12
Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion. J Cell Biol (1990) 3.11
Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team. Lancet (2000) 2.92
Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis (1991) 2.87
Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol (1997) 2.77
Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob Agents Chemother (2000) 2.68
Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg (1983) 2.57
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Primary structure of a Plasmodium falciparum malaria antigen located at the merozoite surface and within the parasitophorous vacuole. J Biol Chem (1988) 2.43
Giardiasis in American travelers to the Soviet Union. J Infect Dis (1974) 2.36
Genetic and biochemical aspects of human blood-group A-, B-, H-, Le-a- and Le-b-specificity. Br Med Bull (1969) 2.20
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg (1986) 2.09
Biochemistry and Genetics of the ABO, Lewis, and P blood group systems. Adv Hum Genet (1980) 2.08
Malarone-donation programme in Africa. Lancet (1997) 2.07
Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis (2000) 2.06
Sensitivity of Plasmodium falciparum isolates to chloroquine in Kisumu and Malindi, Kenya. Am J Trop Med Hyg (1982) 2.04
Plasmodium falciparum: assessment of in vitro growth by [3H]hypoxanthine incorporation. Exp Parasitol (1983) 2.03
Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg (1984) 1.99
An alpha-d-galactosyltransferase associated with the blood-group B character. Biochem J (1968) 1.95
A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol (1987) 1.95
Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med (1975) 1.80
Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene. Proc Natl Acad Sci U S A (1986) 1.77
Differential subcompartmentation of terminal glycosylation in the Golgi apparatus of intestinal absorptive and goblet cells. J Biol Chem (1986) 1.72
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol (1989) 1.71
Evaluation of a commercially available enzyme-linked immunosorbent assay for Giardia lamblia antigen in stool. J Clin Microbiol (1991) 1.70
Infectious diseases and injuries in child day care. Opportunities for healthier children. JAMA (1992) 1.64
Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg (1999) 1.63
Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya. Lancet (1984) 1.61
Characterization of the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum. Mol Biochem Parasitol (1990) 1.55
The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria. Br J Clin Pharmacol (1992) 1.53
The peptide moiety of human-blood-group active glycoproteins associated with the ABO and Lewis groups. Biochem J (1969) 1.49
Molecular and genetic aspects of human blood-group Le-b specificity. Nature (1967) 1.47
Low magnesium and phospholipid content of cell wals of Pseudomonas aeruginosa resistant to polymyxin. Nature (1970) 1.47
The disposition of intramuscular artemether in children with cerebral malaria; a preliminary study. Trans R Soc Trop Med Hyg (1997) 1.46
In vitro antimalarial activity of tetrahydrofolate dehydrogenase inhibitors. Am J Trop Med Hyg (1984) 1.42
Treatment of children with asymptomatic and nondiarrheal Giardia infection. Pediatr Infect Dis J (1991) 1.42
Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. AIDS (1990) 1.40
Inhibition of in vitro growth of Plasmodium falciparum by immune serum from monkeys. J Infect Dis (1981) 1.37
Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro. J Clin Invest (1989) 1.36
Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet (2002) 1.36
Quinine treatment of severe falciparum malaria in African children: a randomized comparison of three regimens. Am J Trop Med Hyg (1991) 1.35
Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother (1998) 1.34
Intestinal parasitism in the United States: update on a continuing problem. Am J Trop Med Hyg (1994) 1.32
Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria. BMJ (1988) 1.31
Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans R Soc Trop Med Hyg (1985) 1.31
Giardiasis in Colorado: an epidemiologic study. Am J Epidemiol (1977) 1.29
The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. Am J Trop Med Hyg (2000) 1.28
Leishmania donovani parasitaemia in Kenyan visceral leishmaniasis. Trans R Soc Trop Med Hyg (1985) 1.28
A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya. J Infect Dis (1983) 1.28
Microsporidia: opportunistic pathogens in patients with AIDS. Prog Clin Parasitol (1991) 1.28
Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine. Trans R Soc Trop Med Hyg (1985) 1.26
An a-N-acetyl-D-galactosaminyltransferase associated with the human blood-group A character. Biochem J (1968) 1.26
The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro. Ann Trop Med Parasitol (1984) 1.25
Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria. J Immunol (1989) 1.24
A new in vitro test for pyrimethamine/sulfadoxine susceptibility of Plasmodium falciparum and its correlation with in vivo resistance in Kenya. Bull World Health Organ (1984) 1.23
In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother (1995) 1.21
Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet (1991) 1.20
Parasite viability during treatment of severe falciparum malaria: differential effects of artemether and quinine. Am J Trop Med Hyg (1995) 1.19
Usage of community-based chloroquine treatment for malaria in Saradidi, Kenya. Ann Trop Med Parasitol (1987) 1.19
Drug-resistant malaria--changing patterns mean difficult decisions. Trans R Soc Trop Med Hyg (1985) 1.18
Disease-surveillance and decision-making after the 1976 Guatemala earthquake. Lancet (1977) 1.17
Safety and immunogenicity of a Plasmodium vivax sporozoite vaccine. Am J Trop Med Hyg (1990) 1.16
Selective stage-specific changes in the permeability to small hydrophilic solutes of human erythrocytes infected with Plasmodium falciparum. Mol Biochem Parasitol (1985) 1.16
Relationship between structure, specificity and genes within the ABO and Lewis blood-group systems. Bibl Haematol (1965) 1.16
Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother (1997) 1.15
Splenic abscess. Report of 10 cases and review of the literature. Am J Med (1976) 1.15
Amebiasis in a mental institution: serologic and epidemiologic studies. Am J Epidemiol (1974) 1.14
Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans R Soc Trop Med Hyg (1985) 1.13
Inhibitory effects of immune monkey serum on synchronized Plasmodium falciparum cultures. Am J Trop Med Hyg (1981) 1.12
Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1993) 1.11
Serum concentrations of penicillin, doxycycline, and ciprofloxacin during prolonged therapy in rhesus monkeys. J Infect Dis (1992) 1.11